Zeven Katty, Dierick Herlinde, Sevenois Matthijs, Baudhuin Henri, Navarro Laurent, Van den Block Sonja, Saliën Jelena, Breckpot Karine, Bridoux Jessica, De Groof Timo W M, Devoogdt Nick
Molecular Imaging and Therapy Research Group (MITH), Vrije Universiteit Brussel, Brussels, Belgium.
Nuclear Medicine Department, Vrije Universiteit Brussel (VUB), Universitair Ziekenhuis Brussel (UZ Brussel), Brussels, Belgium.
Eur J Nucl Med Mol Imaging. 2025 Mar 31. doi: 10.1007/s00259-025-07205-2.
Positron emission tomography remains the most important medical imaging technique for noninvasive imaging. Advances in radiotracer design, particularly those based on antibody(-formats), have broadened diagnostic applications. While minibodies and nanobodies stand out among antibody-type radiotracers due to their unique characteristics and pharmacokinetics, a direct comparison between these formats remains unexplored. In this study, we generated a so-called minabody, a minibody-like protein consisting of a nanobody fused to a CH3 domain, and compared it with its nanobody counterpart in vitro and in vivo upon labeling with various PET radionuclides.
A previously developed human TIGIT-targeting nanobody was reformatted to a minabody format to allow head-to-head comparison of both formats. The minabody and nanobody formats were compared in vitro for binding, specificity and stability. The minabody and/or nanobody formats were labeled with copper-64, gallium-68 or fluor-18 for non-invasive imaging of human TIGIT-expressing tumors by PET/CT over time.
The minabody format showed higher binding affinities compared to the nanobody format. Despite lower binding affinity, the nanobody format outperformed the minabody format as PET imaging tracer showing higher specificity and allowing imaging of human TIGIT expression from 1 to 48 h post-injection upon labeling with copper-64. In addition, copper-64 showed superior tumor uptake and contrast for nanobody imaging compared to gallium-68 and fluor-18.
This study describes the first head-to-head comparison between the minibody and nanobody format for PET imaging. Our results underscore the importance of considering both targeting vector format and the radionuclide to achieve accurate and high-quality PET imaging.
正电子发射断层扫描仍是无创成像最重要的医学成像技术。放射性示踪剂设计的进展,特别是基于抗体(形式)的进展,拓宽了诊断应用。虽然微型抗体和纳米抗体因其独特的特性和药代动力学在抗体型放射性示踪剂中脱颖而出,但这些形式之间的直接比较仍未得到探索。在本研究中,我们生成了一种所谓的微型纳米抗体,这是一种由与CH3结构域融合的纳米抗体组成的类似微型抗体的蛋白质,并在体外和体内用各种正电子发射断层扫描放射性核素标记后,将其与其纳米抗体对应物进行比较。
将先前开发的靶向人TIGIT的纳米抗体重新格式化为微型抗体形式,以便对两种形式进行直接比较。在体外比较微型抗体和纳米抗体形式的结合、特异性和稳定性。微型抗体和/或纳米抗体形式用铜-64、镓-68或氟-18标记,以便通过正电子发射断层扫描/计算机断层扫描随时间对表达人TIGIT的肿瘤进行无创成像。
与纳米抗体形式相比,微型抗体形式显示出更高的结合亲和力。尽管结合亲和力较低,但纳米抗体形式作为正电子发射断层扫描成像示踪剂的表现优于微型抗体形式,显示出更高的特异性,并在用铜-64标记后,能够在注射后1至48小时对人TIGIT表达进行成像。此外,与镓-68和氟-18相比,铜-64在纳米抗体成像中显示出更好的肿瘤摄取和对比度。
本研究描述了微型抗体和纳米抗体形式在正电子发射断层扫描成像方面的首次直接比较。我们的结果强调了考虑靶向载体形式和放射性核素以实现准确和高质量正电子发射断层扫描成像的重要性。